These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effects of reprogramming on genomic imprinting and the application of pluripotent stem cells. Li X; Li MJ; Yang Y; Bai Y Stem Cell Res; 2019 Dec; 41():101655. PubMed ID: 31734645 [TBL] [Abstract][Full Text] [Related]
9. Potentialities of induced pluripotent stem (iPS) cells for treatment of diseases. Chakraborty C; Shah KD; Cao WG; Hsu CH; Wen ZH; Lin CS Curr Mol Med; 2010 Nov; 10(8):756-62. PubMed ID: 20937020 [TBL] [Abstract][Full Text] [Related]
10. Modeling of Autism Using Organoid Technology. Choi H; Song J; Park G; Kim J Mol Neurobiol; 2017 Dec; 54(10):7789-7795. PubMed ID: 27844287 [TBL] [Abstract][Full Text] [Related]
12. Genetic engineering in organoids. Teriyapirom I; Batista-Rocha AS; Koo BK J Mol Med (Berl); 2021 Apr; 99(4):555-568. PubMed ID: 33459801 [TBL] [Abstract][Full Text] [Related]
13. Specific Cell (Re-)Programming: Approaches and Perspectives. Hausburg F; Jung JJ; David R Adv Biochem Eng Biotechnol; 2018; 163():71-115. PubMed ID: 29071403 [TBL] [Abstract][Full Text] [Related]
14. Trials of embryonic stem cells to launch in China. Cyranoski D Nature; 2017 May; 546(7656):15-16. PubMed ID: 28569831 [No Abstract] [Full Text] [Related]
15. How cerebral organoids are guiding brain-cancer research and therapies. Nowogrodzki A Nature; 2018 Sep; 561(7724):S48-S49. PubMed ID: 30258158 [No Abstract] [Full Text] [Related]